The landscape of dementia analysis has advanced considerably with the advent of innovative biomarkers, such as amyloid PET scans, tau imaging, and blood-dependent checks that may detect Alzheimer's pathology yrs before indicators arise. Though these technological developments depict extraordinary progress in knowing neurodegenerative disorders, the